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Abstract
Purpose Earlier, the association of single nucleotide polymor-
phisms (SNPs) with toxicity and efficacy of sunitinib has been
explored in patients with metastatic renal cell carcinoma
(mRCC). Recently, additional SNPs have been suggested as
potential biomarkers. We investigated these novel SNPs for
association with sunitinib treatment outcome in mRCC patients.
Methods In this exploratory study, we selected SNPs in genes
CYP3A4, NR1I2, POR, IL8, IL13, IL4-R, HIF1A and MET
that might possibly be associated with sunitinib treatment out-
come. Each SNP was tested for association with progression-
free survival (PFS) and overall survival (OS) by Cox-
regression analysis and for clinical response and toxicity using
logistic regression.
Results We included 374 patients for toxicity analyses, of
which 38 patients with non-clear cell renal cell cancer
were excluded from efficacy analyses. The risk for hyper-
tension was increased in the presence of the T allele in
IL8 rs1126647 (OR=1.69, 95 % CI=1.07–2.67, P=
0.024). The T allele in IL13 rs1800925 was associated
with an increase in the risk of leukopenia (OR=6.76,
95 % CI=1.35–33.9, P=0.020) and increased prevalence
of any toxicity > grade 2 (OR=1.75, 95 % CI=1.06–2.88,
P=0.028). No significant associations were found with
PFS, OS or clinical response.
Conclusions We show that polymorphisms in IL8 rs1126647
and IL13 rs1800925 are associated with sunitinib-induced
toxicities. Validation in an independent cohort is required.
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Introduction
Several targeted therapies have been approved for the treat-
ment of metastatic renal cell carcinoma (mRCC). Of these, the
tyrosine kinase inhibitor (TKI) sunitinib is widely used as
first-line treatment option [1–4]. The response to sunitinib
varies largely among patients. Only 35 % of mRCC patients
benefit from sunitinib, and about 30 % of patients need dose
reductions due to adverse events of which grades vary among
patients [1, 5, 6]. To optimize treatment efficacy and to min-
imize the risk of adverse events of higher grades, it would be
helpful to predict the individual treatment outcome at the ini-
tiation of therapy. Unfortunately, no biomarkers are yet avail-
able to fulfil this need.
Several studies used a candidate gene approach to select
single nucleotide polymorphisms (SNPs) in genes involved in
the pharmacokinetics and pharmacodynamics of sunitinib.
SNPs and haplotypes in CYP1A1, CYP3A5, ABCB1, ABCG2,
NR1I3, VEGFA, NOS3 (=eNOS), FLT1 (=VEGFR1), KDR
(=VEGFR2), FLT-4 (=VEGFR3) and FLT3 have been de-
scribed to have an association with either toxicity or efficacy
of sunitinib (P<0.05) in mRCC patients [5–11]. The associa-
tions of CYP3A5 and ABCB1 with dose reductions and effi-
cacy, respectively, have been confirmed recently [12]. Not all
clinical outcomes can be explained by these potential
biomarkers, which make identification of other markers pos-
sibly associated with clinical outcome an attractive prospect.
Novel SNPs in CYP3A4, NR1I2, POR, IL8, IL4-R, IL13,
HIF1A and MET have been reported in patients with RCC,
either prognostic or associated with treatment outcome, and
might play a role in sunitinib treatment outcome (Table 1)
[13–20]. In some studies on these novel SNPs, the TKI
pazopanib was given to patients with mRCC. Sunitinib and
pazopanib have similar efficacy and both are used as first-line
treatment options [2]. Further, both drugs have similarities in
their metabolic pathways and affected targets, because of
which SNPs associated with pazopanib outcome might also
bemeaningful for the sunitinib treatment outcome, i.e. toxicity
or efficacy [21]. The T allele of SNP rs35599367 in CYP3A4
(CYP3A4*22) was associated with decreased clearance of su-
nitinib [13–15]. The T allele of SNP rs3814055 in NR1I2 was
associated with a reduction in response to pazopanib and in-
ferior progression-free survival (PFS) from sunitinib and
pazopanib in univariate analysis [6, 16]. The TT genotype of
SNP rs1057858 in the P450 oxidoreductase gene (POR*28)
was associated with higher CYP3A activity [17, 18]. Variant
alleles of rs4073 and rs1126647 in IL8 were associated with
an inferior PFS on pazopanib treatment [16]. SNPs rs1800925
and rs20541 in IL13 and rs180510 in IL4-R are likely to in-
fluence tumour immune response and carcinogenesis [19].
The AG genotype of rs11549467 in HIF1A compared to
wild-type GG was associated with a decreased PFS and a
reduced response rate on pazopanib treatment [16]. The A-
allele of SNP rs11762213 in MET was associated with an
increased risk of recurrence or death in RCC patients [20].
Table 1 Polymorphisms in candidate genes in the current study. Genetic polymorphisms were included if in previous exploratory studies associations
were reported with a P value <0.05
Gene SNP Reported results References
CYP3A4 rs35599367C>T CYP3A4*22 is associated with decreased CYP3A4
expression and decreased clearance of sunitinib.
Elens et al. [13, 14]
Diekstra et al. [15]
NR1I2 rs3814055C>T T allele is associated with reduction of response
to pazopanib and inferior PFS on sunitinib and pazopanib.
van der Veldt et al. [6]
Xu et al. [16]
POR*28 rs1057868C>T POR*28 is associated with higher in vivo CYP3A activity. de Jonge et al. [17]
Oneda et al. [18]
IL8 rs4073T>A AA shows inferior PFS of pazopanib compared to wild-type TT. Xu et al. [16]
rs1126647A>T TT shows inferior PFS of pazopanib compared to wild-type AA. Xu et al. [16]
Correlated SNPs rs4073T>A and
rs1126647A>T
Inferior PFS for variant genotypes (r4073 AA+rs1126647 TT)
compared to wild types (rs4073 TT+rs1126647 AA)
Xu et al. [16]
HIF1A rs11549467G>A AG genotype is associated with inferior PFS and reduced
response rate of pazopanib compared to wild-type GG.
Xu et al. [16]
IL4-R rs1805010T>C CT/TT genotype is associated with decreased risk of RCC
compared to CC genotype.
Chu et al. [19]
IL13 rs1800925C>T TT genotype is associated with decreased risk of RCC. Chu et al. [19]
rs20541C>T
MET rs11762213G>A A-allele is associated with an increased risk of recurrence or death. Schutz et al. [20]
SNP single nucleotide polymorphism, PFS progression-free survival, OS overall survival
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In this exploratory study, we evaluated the polymorphisms
in the above-mentioned genes for possible associations with
toxicity or efficacy of sunitinib in a large cohort of mRCC
patients.
Methods
Study population
Patient data were collected from three exploratory studies
(SUTOX, SOGUG and CCF) between the years 2004 and
2010 (Supplementary document 1) [12]. SUTOX samples
were anonymized by a third party, according to the instruc-
tions stated in the Codes for Proper Use and Proper Conduct in
the Self-Regulatory Codes of Conduct (www.federa.org). The
study was conducted in accordance with the Declaration of
Helsinki and approved by the medical ethics review board of
all participating groups. Patients provided their written
informed consent for participation [12].
Study endpoints
PFS, defined as the time in months between the first day of
sunitinib treatment and the date of progressive disease (PD)
according to Response Evaluation Criteria in Solid Tumours
(RECIST) v.1.0 or v1.1, was used as the primary endpoint to
assess efficacy. Another endpoint was overall survival (OS),
which was measured from the first day of sunitinib treatment
until death or time of last follow-up.
We classified objective clinical response into three catego-
ries: (i) partial and complete response, (ii) stable disease and
(iii) progressive disease (according to RECIST).
Specific sunitinib-related adverse events, i.e. thrombocyto-
penia, leukopenia, mucosal inflammation, hand-foot syn-
drome, hypertension and any toxicity > grade 2, were collect-
ed for this study (Supplementary document 1) [12].
Statistical analysis
For univariate analysis, a log-rank test was used for the
association of each SNP with PFS and OS, and a chi-
square test for clinical response and toxicity. SNPs with
a P value <0.1 were included in the multivariate model.
Based on previous results, we included well-established
covariates age, gender and Heng prognostic risk group
in the multivariate model for correction of PFS and OS
[22]. In addition, the CGT haplotype of ABCB1 was
also used as covariate in multivariate Cox model be-
cause of the previously confirmed significant association
with PFS [6, 12]. For multivariate analysis of clinical
response, we also included age, gender and Heng prog-
nostic risk group as covariates. For multivariate analysis
on toxicity endpoints, no biomarker was widely validat-
ed, so we corrected for age and gender. Because this
association study used data from three study groups
(SUTOX, SOGUG and CCF), study group was also
tested as a covariate for all endpoints. It was not needed
to correct for previous treatment in efficacy analyses,
because this was already justified by using study group
as a covariate.
Reported results from the multivariate analysis with a P
value <0.05 were considered clinically significant. All tests
were two-sided and carried out by SPSS Statistical Package
for Windows (version 20.0 Armonk, NY: IBM Corp).
Results
Patient characteristics
A total of 374 patients with mRCC treated with sunitinib were
included for association analyses on toxicity endpoints. For
efficacy analyses, only clear cell subtypes (N=336) were in-
cluded (Fig. 1). Patient characteristics are presented in Table 2.
Median age of patients was 61 years, and most were men of
Caucasian ethnicity. The majority of patients had undergone
nephrectomy. For the clear cell subjects, the good or interme-
diate Heng prognostic risk group consisted of 73 % of the
patients. Forty-five percent (N=143) of patients showed a par-
tial response (PR) or complete response (CR) to sunitinib.
95.7 to 99.5 % of patients had no toxicities at baseline.
Within four cycles of sunitinib treatment, any grade of throm-
bocytopenia was observed in 61 % of patients, mucosal in-
flammation in 59 %, leukopenia in 49 %, hand-foot syndrome
in 41 % and hypertension in 38 %. Twenty-six percent of
patients developed any toxicity > grade 2 (Supplementary
Table S1).
For clear cell subtypes, median follow-up times for PFS
and OS analysis were 43 and 49 months, respectively. Median
PFS and OS of patients were 16 and 26 months, respectively.
Genotyping
IL8 rs4073 was excluded from statistical analysis because the
call rate was less than 95 %. The SNP genotype call rate for
the remaining SNPs ranged from 97.6 to 99.7 %. All SNPs
were in Hardy-Weinberg equilibrium (HWE) (P>0.05 and χ2
<3.84). The allele frequencies of genotyped polymorphisms
were similar as reported in the National Center for Biotech-
nology Information (NCBI) SNP database [23]. Only three
patients with the HIF1A rs11549467 heterozygous genotype
were detected. As a consequence, the effects of this SNP could
not be analysed.
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Genetic association analysis
No significant associations between SNPs and PFS, OS or
objective response to sunitinib were observed in this study.
Although not significant, A-allele carriers of MET
rs11762213 had a better PFS compared to wild-type GG
(HR=0.63, 95 % CI=0.38–1.05, P=0.076), adjusted for
age, gender, Heng prognostic risk group, study group and
CGT haplotype in ABCB1 (Table 3).
In multivariate toxicity analysis, the T allele of IL8
rs1126647 was associated with an increased risk of hyperten-
sion compared to wild-type AA (OR=1.69, 95 % CI=1.07–
2.67, P=0.024) after adjustment by age, gender and study
group. Presence of the IL13 rs1800925 Tallele was associated
with an increased risk of leukopenia (OR=6.76, 95 % CI=
1.35–33.9, P=0.020) and also with development of any tox-
icity > grade 2 (OR=1.75, 95 % CI=1.06–2.88, P=0.028)
(Table 3).
Discussion
In the present study, we analysed eight candidate SNPs in
seven genes for potential association with response and/or
toxicity of sunitinib in a large cohort of mRCC patients. To
our knowledge, we report for the first time that genetic poly-
morphisms in interleukin genes IL8 and IL13 are associated
with the occurrence of clinically relevant adverse events from
sunitinib. Patients carrying a T allele of IL8 rs1126647 had an
increased risk of hypertension compared to wild-type AA
(OR=1.69). T carriers of IL13 rs1800925 had an increased
risk of leukopenia (OR=6.76) and an increased risk of any
toxicity > grade 2 (OR=1.75).
Hypertension is a frequent toxicity caused by TKIs. The
potential mechanism is suggested to be related to inhibition of
VEGFR-2 and decrease of nitric oxide, resulting in vasocon-
striction and elevated blood pressure [8, 24]. It has been rec-
ognized that IL8, possibly by upregulating VEGF levels
through NFkappaB [25, 26], can play a role in stimulating
VEGFR-2 transactivation. In our data, presence of the variant
allele in IL8 rs1126647A>T is significantly associated with
hypertension. IL8 rs1126647A>T is in linkage with IL8
rs4073T>A (r2=0.78) [16]. It was shown that a haplotype of
IL8, including the variant allele of rs4073T>A and
rs1126647A>T, was associated with increased IL8 expression
[27]. In contrast, Amaya et al. [28] have reported that the
variant allele of rs4073 was associated with a lower produc-
tion of IL8. It remains to be elucidated whether particular
SNPs in IL8 have prognostic or even predictive significance
in metastatic renal cell carcinoma.
The occurrence of hypertension is a well-known predictor
for increased survival in metastatic renal cell carcinoma treat-
ed with a TKI [29]. In addition to an increased occurrence of
hypertension, patients with the variant allele in IL8
Fig. 1 Patient flowchart on
included patients. Fifty-six
patients had to be excluded from
association analyses because of
individual genotyping call rates
<80 % (N=6), relocation to
another medical center during
follow-up (N=10), double patient
(N=1), a change to another
treatment than sunitinib directly
after enrolment (N=1) or non-
clear cell subtypes (N=38). A
total of 374 sunitinib-treated clear
cell mRCC patients were
available for analysis of toxicity
in the present study. For efficacy
analysis, 336 sunitinib-treated
clear cell mRCC patients were
available [12]
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rs1126647A>Tshowed a trend towards improved PFS/OS (22
vs 14 months for median PFS and 40 vs 25 months for median
OS), although the differences between groups did not reach
statistical significance. One possible reason for the lack of
statistical significance in the above association may be the
∼2 fold larger (n=544) sample size of the study from Rini
et al. [29]. Xu et al. [16] described an inferior PFS of
pazopanib for carriers of the variant allele of IL8
rs1126647A>T. In a follow-up study, Xu et al. [30] reported
that the variant allele of IL8 rs1126647A>Twas significantly
associated with worse OS in mRCC patients treated with
pazopanib or sunitinib, but could not confirm the initial asso-
ciation with PFS. Unfortunately, Xu et al. do not report data on
associations between IL8 rs1126647 and hypertension. In ad-
dition, many factors can have an impact on OS, including
baseline conditions and previous and posterior treatments.
Therefore, it is not possible to directly compare the association
of IL8 rs1126647 and hypertension/survival between the two
datasets and further study in an independent cohort is
required.
We observed an increased risk of leukopenia in carriers of
the variant allele of IL13 rs1800925C>T. Leukopenia is a
common haematologic adverse event in sunitinib treatment
of which the mechanism remains uncertain. It was reported
that VEGF and its receptors (VEGFR) are essential for devel-
opment of aberrant haematopoiesis, including leukopenia
[31]. Shen et al. [32] have reported that VEGFR-2 can be
upregulated by IL13. The T allele of IL13 rs1800925 has been
found to be associated with increased IL13 protein function
[33].
Little is known about the effects of SNPs in IL8 and IL13,
but it is likely that these SNPs will either increase or decrease
the protein expression of IL8 and IL13 proteins [24–26, 29,
31–34]. It also remains unclear whether the function of these
interleukins will affect TKI treatment outcome and if and how
these interleukin proteins would influence the VEGF(R) path-
way directly or indirectly [25–28, 30–36]. Xu et al. [30] spec-
ulate that patients with the IL8 variants having a high IL8
expression may have more aggressive tumours, and therefore
a reduced survival. However, it is difficult to hypothesize be-
cause we noticed conflicting results: Hacking et al. [27] re-
ported increased expression for IL8 variants, while a more
recent paper of Amaya et al. [28] reported the opposite effect
on IL8 expression. If variant alleles in IL8 and IL13 SNPs alter
protein expression and have an effect on VEGF-R2, a stronger
inhibition of VEGF-R2 in the concomitant presence of suni-
tinib would explain our results on a higher risk for any toxic-
ity, including hypertension and leukopenia.
HIF1A protein regulates the transcription of a large
number of genes that respond to hypoxia, among which
is angiogenesis. The A-allele frequency of HIF1A
rs11549467 in our cohort was 0.45 %, which is lower
than that (A=3.0 %) reported by Xu et al. [16], but cor-
responds with the result (A=0.6 %) from Beuselinck et al.
[10]. The difference in A-allele frequency is potentially
caused by the subject selection. Of note, the subjects re-
cruited here and in the study of Beuselinck typically have
Western European ancestry, whereas the patients in Xu’s
study are mostly from Eastern Europe [10, 16].
Table 2 Patient characteristics
Characteristic Efficacy cohort
(N=336)
Toxicity cohort
(N=374)
Age
Median 61 61
Percentiles (25th, 75th) 55, 69 54, 68
BSA
Median 1.98 1.96
Percentiles (25th, 75th) 1.82, 2.13 1.82, 2.12
Race
White 324 (96 %) 358 (96 %)
Asian 3 (0.89 %) 3 (0.80 %)
Black 5 (1.5 %) 8 (2.1 %)
Arabian 3 (0.89 %) 4 (1.0 %)
Latin American 1 (0.30 %) 1 (0.27 %)
Gender
Male 229 (68 %) 258 (69 %)
Female 107 (32 %) 116 (31 %)
Clinical response
PR+CR 143 (43 %) 149 (40 %)
SD 130 (39 %) 149 (40 %)
PD 43 (13 %) 55 (15 %)
Unknown 20 (6.0 %) 21 (5.6 %)
Heng prognostic risk groupa
Good (0 risk factor) 64 (19 %) 68 (18 %)
Intermediate (1–2 risk factors) 182 (54 %) 197 (53 %)
Poor (3–6 risk factors) 90 (27 %) 108 (29 %)
Metastatic sites
1 91 (27 %) 105 (28 %)
2 137 (41 %) 149 (40 %)
≥3 104 (31 %) 116 (31 %)
Prior nephrectomy
No 49 (15 %) 63 (17 %)
Yes 283 (85 %) 307 (82 %)
Prior treatment
No 254 (76 %) 276 (74 %)
Yes 82 (24 %) 98 (26 %)
BSA body surface area, CR complete response, PR partial response, SD
stable disease, PD progressive disease
a Patients are classified according to the six Heng risk criteria: poorWHO
performance status (≥2), low haemoglobin (<lower limit of normal), high
calcium (>upper limit of normal) and time from initial diagnosis to treat-
ment with sunitinib (<1 year), neutrophil count (>upper limit of normal)
and thrombocytes (>upper limit of normal)
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This study was conducted in a relatively large cohort,
which decreases the chance for false-positive findings. In ad-
dition to Xu et al. [30], we have tested on toxicity as well as
efficacy endpoints, which is essential for clinical interpreta-
tion. SNPs could influence the drug exposure to the TKI and
consequently have an effect on both adverse events, PFS and
OS. Because this study only presents explorative findings
without external validation, and our results are based onmain-
ly Caucasian subjects, extrapolation to the entire mRCC pop-
ulation is difficult.
To capture adverse events that occur later on in treatment,
all toxicity outcomes were recorded and evaluated up to four
cycles of sunitinib treatment. In our cohort, hypertension and
fatigue have a large contribution in the endpoint any toxicity >
grade 2. Because it is difficult to evaluate fatigue objectively,
we did not test fatigue as separate toxicity endpoint. Since our
study represents data collected from 2004 to 2010, it is likely
that clinical practice (i.e. toxicity management) has evolved in
the course of time. In earlier years with limited experience on
sunitinib treatment, dose reductions were applied in the case
of grade 3 or 4 toxicities. Nowadays, physicians anticipate on
the development of severe adverse events by already reducing
the dose on the occurrence of grade 2 toxicity. However, we
did not observe a difference in dose reductions between earlier
years and later years (data not shown). Further, our dataset
lacks sufficiently detailed information on the reasons and time
points of dose reductions.
Our SNP selection was based on reported associations
with toxicity and efficacy outcomes on treatment and the
risk of developing RCC. SNPs are often categorized as
being either predictive or prognostic biomarkers. Howev-
er, this distinction may not have to be as rigorous as we
currently assume. In fact, prediction and prognosis may
be strongly correlated. Antitumour treatment can have a
different effect in patients with a more aggressive tumour
type that is possibly caused by an underlying SNP. For
example, high IL8 protein levels in RCC are considered to
have a poor prognosis [35]. However, elevated IL8 levels
investigated in preclinical models resulted in resistance to
sunitinib, which would be considered predictive [36].
Functional studies on immunological and angiogenic fac-
tors and a genome-wide approach can help us in under-
standing the mechanisms on the predictive or prognostic
character of the SNPs.
Table 3 Univariate and multivariate analyses for SNPs associated with sunitinib treatment outcome
Treatment outcome Number of patients Univariate analyses Multivariate analyses
HR or OR 95 % CI P value HR or OR 95 % CI P value
PFS
MET rs11762213 G>A 0.58 0.36–0.96 0.032 0.63 0.38–1.05 0.076a
GG versus 302
AG+AA 33
Hypertension
IL8 rs1126647 A>T 1.70 1.08–2.68 0.022 1.69 1.07–2.67 0.024b
AA versus 128
AT versus 174
TT 61
Thrombocytopenia
IL13 rs20541 C>T 1.97 0.90–4.35 0.092 1.87 0.82–4.23 0.136b
CC versus 235
CT+TT 117
Leukopenia
IL13 rs1800925 C>T 6.13 1.25–30.0 0.025 6.76 1.35–33.9 0.020b
CC versus 232
CT+TT 137
Any toxicity > grade 2
IL13 rs1800925 C>T 1.91 1.15–3.15 0.012 1.75 1.06–2.88 0.028b
CC versus 234
CT+TT 137
HR hazard ratio, OR odds ratio, CI confidence interval, PFS progression-free survival
a Adjusted by age, gender, Heng prognostic risk group, study center and ABCB1 haplotype
bAdjusted by age, gender and study center
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In conclusion, this study suggests a relationship between
interleukin genes IL8 and IL13 and the development of
sunitinib-induced adverse events. Further validation in an in-
dependent cohort is warranted to confirm our findings. In
addition, we consider functional studies on IL8 and IL13, with
respect to regulation of VEGF(R) genes and sVEGF(R) plas-
ma levels, to be crucial for our understanding of the mecha-
nisms involved in sunitinib exposure and occurrence of ad-
verse events.
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